688526.SH
Wuhan Keqian Biology Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 12.97
−0.92%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenCNY 12.38
From 52W high−4.28%
Volume955607.00
Market capCNY 6.05B
P/E (TTM)14.4x
P/S (TTM)6.2x
Div yield5.17%
Key dataSep 18, 2026
Open
CNY 12.38
From 52W high
−4.28%
Volume
955607.00
Market cap
CNY 6.05B
ValuationView details →
P/E (Fwd)
9.9x
EV/EBITDA
9.4x
P/E (TTM)
14.4x
RSI (14)
41.1
MomentumView details →
1D Return
−0.92%
YTD Return
—
Similar companies
Latest newsMore news →
Kequan Biotechnology received approval from China's Ministry of Agriculture and Rural Affairs for its trivalent inactivated vaccine against feline rhinotracheitis, calicivirus disease and panleukopenia, obtaining a New Veterinary Drug Registration Certificate with a 3-year monitoring period.6d agoKeqian Biology announced its first-half 2026 results: net profit attributable to shareholders was 116 million yuan, down 47.37% year-on-year.25d agoKeqian Biology received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its avian adenovirus (group I, type 4) inactivated vaccine (HB-2 strain) to be registered as a new veterinary drug, and obtained the new veterinary drug registration certificate.27d ago